Literature DB >> 27295996

Sebaceous carcinoma of the parotid gland: a case report and review of the literature.

El Amin Marnouche1, Abdelhak Maghous2, Selma Kadiri2, Soufiane Berhili2, Asmae Touil2, Fouad Kettani3, Sanaa Majjaoui2, Hanane Elkacemi2, Tayeb Kebdani2, Noureddine Benjaafar2.   

Abstract

BACKGROUND: Sebaceous carcinoma is a rare malignancy primarily with aggressive growth affecting the cutaneous tissues of the periocular region. Sebaceous carcinoma of the parotid gland is exceedingly rare, with only 32 cases reported in the literature. Our case brings this total to 33. CASE
PRESENTATION: We present a case of a 57-year-old Moroccan woman with a firm, painless, slowly enlarging swelling at her left parotid area, with normal overlying skin and no palpable neck nodes. Parotidectomy with facial nerve preservation was performed, and microscopic examination showed sebaceous carcinoma. Then, she underwent adjuvant radiotherapy. With a follow up of 20 months, head and neck computed tomography revealed no recurrence.
CONCLUSIONS: The optimal treatment is unclear. With more cases reported, clinicopathological characteristics and histogenesis are increasingly understood. Therefore the treatment for this rare tumor continues to evolve.

Entities:  

Keywords:  Parotid gland; Sebaceous carcinoma

Mesh:

Year:  2016        PMID: 27295996      PMCID: PMC4906575          DOI: 10.1186/s13256-016-0946-z

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


Background

Sebaceous carcinoma (SC) is a rare neoplasm with aggressive growth. In 75 % of all cases [1] this tumor presents in the cutaneous tissues of the periocular region, typically on the eyelid, but it has also been described less commonly in other locations (70 % in the head and neck region [1]), including as a primary tumor of the parotid gland [2]. The parotid gland is the second most frequent site for SC in the head and neck region [3]. In 1953, Foote and Frazell first reported in a review of salivary gland tumors a case of sebaceous adenoma, specifying that the listing of a single example of this tumor type is more an anticipation, than a proof, of its actual existence [4]. Six years later, Rauch and Masshoff described a malignant counterpart (SC) in the parotid gland [5]. Up to February 2015, there have been 32 documented cases of SC in the parotid gland [3, 6–28] with our case bringing the total to 33. Its clinicopathological characteristics and histogenesis are not fully understood because of its rarity. We present a case of SC of the parotid gland with a brief review of the literature.

Case presentation

A 57-year-old Moroccan woman with no tobacco smoking history presented to an otolaryngology clinic with the chief complaint being a lump over the left side of her parotid region, for 9 months’ duration. Her anamnesis did not reveal a similar case in her family. A physical examination demonstrated a firm, painless, slowly enlarging swelling, with normal overlying skin and no palpable neck nodes. Ultrasonography of her neck revealed a 2.7 × 2.2 cm, mixed component nodule with increased vascularity (Fig. 1). Based on clinical and ultrasonography findings, parotidectomy with facial nerve preservation was performed without lymph node neck dissection.
Fig. 1

Ultrasonography revealed a mixed component nodule of the left parotid

Ultrasonography revealed a mixed component nodule of the left parotid Final pathology revealed a SC that was a low-grade tumor. On macroscopic examination, the mass was ill defined and white; it measured 1.5 × 2 cm. Microscopic examination demonstrated malignant proliferation composed of cells organized in nests and bays, with moderate to marked cytonuclear atypia, and a mixture of well-differentiated sebocytes and atypical basaloid cells. Mitotic figures were present (two to four per high-power field). No vascular invasion was demonstrated (Fig. 2). Immunohistochemistry was not performed.
Fig. 2

Malignant proliferation composed of cells organized in nests and bays of different sizes, with moderate to marked cytonuclear atypia, and a mixture of well-differentiated sebocytes and atypical basaloid cells

Malignant proliferation composed of cells organized in nests and bays of different sizes, with moderate to marked cytonuclear atypia, and a mixture of well-differentiated sebocytes and atypical basaloid cells She was referred to our institution. We proposed a lymph node dissection but she refused further surgery. Postoperative computed tomography (CT) was performed and confirmed no residual disease (Fig. 3) and no neck nodes. A chest X-ray was also performed. Therefore, she was classified stage II according to the seventh edition of the American Joint Committee on Cancer’s (AJCC) AJCC Cancer Staging Manual. She completed a course of three-dimensional conformal radiation therapy, indicated by the close margins, without chemotherapy. Two oblique fields (6 MV) were used to deliver 66 Gy with 2 Gy per fraction in parotid bed and an anterior field (6 MV) to deliver 50Gy, 2Gy per a day to ipsilateral neck lymph node (level II to IV).
Fig. 3

Postoperative computed tomography scan showing no residual tissue in parotid space

Postoperative computed tomography scan showing no residual tissue in parotid space With a follow up of 20 months, head and neck CT revealed no recurrence and no adverse event was noted.

Discussion

Sebaceous glands are found in an estimated 10 to 40 % of normal parotid glands and 6 to 10 % of submandibular glands [29, 30]. However, malignant sebaceous salivary gland tumors are extremely rare, making up less than 0.2 % of all major salivary glands tumors [30]. In addition to parotid gland, salivary gland SC has been identified in the submandibular gland, oral cavity, sublingual gland, vallecula, epiglottis, and hypopharynx, totaling 47 SCs of salivary origin neoplasms [6]. These sebaceous elements appeared to originate from the blind-ending intercalated and striated ducts. There is also immunohistochemical evidence to show that SC originates from pluripotential duct cells; ultrastructural and immunohistochemical observations of the tumor revealed coexistence of sebaceous and glandular differentiations in some tumor cells. Tumor cells with lipid granules often participated in the formation of glandular structures or exhibited intracytoplasmic lumina, and immunohistochemical localization of lactoferrin and secretory component, the functional markers of ductal epithelium of salivary gland, was demonstrated not only in duct-forming tumor cells but also in many sebaceous tumor cells. It seems likely that SC originates from pluripotential duct cells which can differentiate into sebaceous, ductal, and mucous cells [24]. The age range of the affected patients was found to be 17 to 93 years, the maximum incidence for all the primary salivary gland sebaceous tumors occurred in the sixth and seventh decades [20]. The sex ratio is 1:1 [11]. The patients often presented with a painless, slow-growing, asymptomatic swelling, leading to delayed diagnosis or misdiagnosis. But some had experienced pain and there were a few cases with facial paralyses [11]. On histological examination, SC ranged from 0.6 to 9.5 cm in greatest dimension and varied from yellow, tan-white, grayish-white, white, to pale pink. The tumors are frequently well circumscribed or partially encapsulated, with pushing or locally infiltrating margins. Cellular pleomorphism and cytologic atypia are uniformly present and are much more prevalent than in sebaceous adenomas. Tumor cells may be arranged in multiple variably sized nests or in sheets and have hyperchromatic nuclei surrounded by abundant clear vacuolated to eosinophilic cytoplasm. Cellular pleomorphism and atypia varies from mild to severe. Areas of cellular necrosis and fibrosis are commonly found. Perineural invasion was observed in more than 20 % of tumors, whereas vascular invasion was extremely infrequent. Rare oncocytes and foreign body giant cells with histiocytes may be observed, but lymphoid tissue with follicles or subcapsular sinuses is not seen. Identification of sebocytes is the key morphologic clue to this entity, as is the absence of matrix protein typically seen in basal cell adenomas and pleomorphic adenomas. Neither the squamous component nor the goblet cells of mucoepidermoid carcinoma are seen in SC, and a mucin stain will be negative. SC does not show the cribriform growth pattern seen in adenoid cystic carcinoma, and is less likely to show perineural invasion. Other uncommon tumors of the parotid with sebaceous differentiation include sebaceous adenoma, which is usually sharply circumscribed, sebaceous lymphadenoma, which contains abundant lymphocytes, similar to a Warthin tumor, and sebaceous lymphadenocarcinoma, which shows adjacent areas of typical sebaceous lymphadenoma [29]. Because of its rarity, a conclusion regarding optimal therapy for this malignancy is lacking. However, treatment is based on surgery with wide surgical excision for low-grade and low-stage carcinomas. Adjunctive radiation therapy is recommended for higher stage and higher grade tumors but also in the case of positive margins. Radical parotidectomy and elective neck dissection should be considered for tumors with marked cytologic atypia or involvement of the facial nerve [6]. SCs may recur and they will rarely metastasize; at least six cases of SC of the salivary glands have been described with local recurrence and metastasis [31]. The overall 5-year survival rate is 62 %, significantly less than the survival rate for similar tumors arising in the skin and orbit (84.5 %) [32].

Conclusions

With more cases reported, clinicopathological characteristics and histogenesis are increasingly understood. Therefore the treatment for this rare tumor continues to evolve.

Abbreviations

CT, computed tomography; SC, sebaceous carcinoma
  30 in total

1.  [Sialoma resembling sebaceous gland].

Authors:  S RAUCH; W MASSHOFF
Journal:  Frankf Z Pathol       Date:  1959

2.  Tumors of the major salivary glands.

Authors:  F W FOOTE; E L FRAZELL
Journal:  Cancer       Date:  1953-11       Impact factor: 6.860

3.  [The significance of sebaceous cells and sebaceous glands in parotid tumors (author's transl)].

Authors:  K O Schmid; W Albrich
Journal:  Virchows Arch A Pathol Pathol Anat       Date:  1973-05-28

4.  Sebaceous cell carcinoma.

Authors:  E Constant; M S Leahy
Journal:  Plast Reconstr Surg       Date:  1968-05       Impact factor: 4.730

5.  Sebaceous cell carcinoma of the parotid region. A review of the literature and a case report.

Authors:  H Silver; M A Goldstein
Journal:  Cancer       Date:  1966-12       Impact factor: 6.860

6.  Sebaceous carcinoma of the parotid gland.

Authors:  A J Mighell; L F Stassen; J V Soames
Journal:  Dentomaxillofac Radiol       Date:  1996-01       Impact factor: 2.419

7.  Sebaceous neoplasms of salivary gland origin. Report of 21 cases.

Authors:  D R Gnepp; R Brannon
Journal:  Cancer       Date:  1984-05-15       Impact factor: 6.860

8.  Sebaceous carcinoma of the parotid gland: report of a case and review of the literature.

Authors:  G Granström; F Aldenborg; P H Jeppsson
Journal:  J Oral Maxillofac Surg       Date:  1987-08       Impact factor: 1.895

9.  Sebaceous carcinoma of the parotid gland in a black patient. A case report.

Authors:  T P Grieve; E Saragas; A Mannell
Journal:  S Afr Med J       Date:  1986-01-18

10.  Sebaceous carcinoma of the parotid gland: a case report.

Authors:  Yohei Takada; Kohei Kawamoto; Susumu Baba; Tomoko Takada; Toshiya Inoue; Koichi Tomoda
Journal:  Case Rep Oncol       Date:  2015-02-21
View more
  2 in total

1.  Primary or metastatic lung cancer? Sebaceous carcinoma of the thigh: A case report.

Authors:  Xiao-Lin Wei; Qing Liu; Qiang-Lin Zeng; Hui Zhou
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

2.  18F-FDG PET/CT for Response Assessment in Pediatric Sebaceous Carcinoma of the Parotid Gland.

Authors:  Adrien Holzgreve; Thomas Pfluger; Irene Schmid; Orlando Guntinas-Lichius; Wolfgang G Kunz; Jens Ricke; Peter Bartenstein; Nathalie L Albert; Marcus Unterrainer
Journal:  Diagnostics (Basel)       Date:  2020-11-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.